Christopher S. Burgey

2.7k total citations
40 papers, 2.0k citations indexed

About

Christopher S. Burgey is a scholar working on Organic Chemistry, Molecular Biology and Psychiatry and Mental health. According to data from OpenAlex, Christopher S. Burgey has authored 40 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Organic Chemistry, 14 papers in Molecular Biology and 14 papers in Psychiatry and Mental health. Recurrent topics in Christopher S. Burgey's work include Migraine and Headache Studies (13 papers), Trigeminal Neuralgia and Treatments (8 papers) and Neuropeptides and Animal Physiology (7 papers). Christopher S. Burgey is often cited by papers focused on Migraine and Headache Studies (13 papers), Trigeminal Neuralgia and Treatments (8 papers) and Neuropeptides and Animal Physiology (7 papers). Christopher S. Burgey collaborates with scholars based in United States, United Kingdom and China. Christopher S. Burgey's co-authors include David A. Evans, Marisa C. Kozlowski, Steven W. Tregay, Kevin R. Campos, Tomáš Vojkovský, Nick A. Paras, Daniel V. Paone, James Z. Deng, Richard J. Staples and Jerry A. Murry and has published in prestigious journals such as Journal of the American Chemical Society, Neurology and Biochemistry.

In The Last Decade

Christopher S. Burgey

39 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christopher S. Burgey United States	21	1.4k	402	384	290	213	40	2.0k
Daniel V. Paone United States	15	744 0.5×	283 0.7×	73 0.2×	216 0.7×	154 0.7×	27	1.1k
J. Delarge Belgium	26	693 0.5×	689 1.7×	91 0.2×	122 0.4×	325 1.5×	115	1.8k
Pauline Chiu Hong Kong	33	2.2k 1.6×	820 2.0×	460 1.2×	67 0.2×	177 0.8×	127	3.2k
Duncan Shaw United Kingdom	18	553 0.4×	214 0.5×	113 0.3×	81 0.3×	103 0.5×	40	906
Wenhu Duan China	33	1.9k 1.3×	1.5k 3.7×	378 1.0×	38 0.1×	304 1.4×	109	3.4k
Leggy A. Arnold United States	32	1.9k 1.4×	1.3k 3.3×	890 2.3×	37 0.1×	355 1.7×	114	3.6k
Shawn P. Maddaford Canada	18	563 0.4×	253 0.6×	70 0.2×	103 0.4×	59 0.3×	34	915
Methvin Isaac Canada	20	543 0.4×	604 1.5×	58 0.2×	60 0.2×	251 1.2×	42	1.2k
Ruth E. TenBrink United States	17	470 0.3×	350 0.9×	42 0.1×	119 0.4×	182 0.9×	33	987
T. G. Murali Dhar United States	24	1.1k 0.8×	668 1.7×	103 0.3×	75 0.3×	400 1.9×	67	2.0k

Countries citing papers authored by Christopher S. Burgey

Since Specialization

Citations

This map shows the geographic impact of Christopher S. Burgey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher S. Burgey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher S. Burgey more than expected).

Fields of papers citing papers by Christopher S. Burgey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher S. Burgey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher S. Burgey. The network helps show where Christopher S. Burgey may publish in the future.

Co-authorship network of co-authors of Christopher S. Burgey

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher S. Burgey. A scholar is included among the top collaborators of Christopher S. Burgey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher S. Burgey. Christopher S. Burgey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vardigan, Joshua D., Xiaoping Zhou, Thomas W. Rosahl, et al.. (2025). Humanized NaV1.8 rats overcome cross-species potency shifts in developing novel NaV1.8 inhibitors. PubMed. 18. 100182–100182. 1 indexed citations

Paone, Daniel V., Kausik K. Nanda, Jing Li, et al.. (2022). Lead optimization of cathepsin K inhibitors for the treatment of Osteoarthritis. Bioorganic & Medicinal Chemistry Letters. 74. 128927–128927. 6 indexed citations

Roecker, Anthony J., M. E. Layton, Michael J. Kelly, et al.. (2021). Discovery of Arylsulfonamide Na _v 1.7 Inhibitors: IVIVC, MPO Methods, and Optimization of Selectivity Profile. ACS Medicinal Chemistry Letters. 12(6). 1038–1049. 8 indexed citations

Ballard, Jeanine, Joshua D. Vardigan, Fuqiang Zhao, et al.. (2021). Translational Pharmacokinetic–Pharmacodynamic Modeling of NaV1.7 Inhibitor MK-2075 to Inform Human Efficacious Dose. Frontiers in Pharmacology. 12. 786078–786078. 5 indexed citations

Moore, Eric L., Mark E. Fraley, Ian M. Bell, et al.. (2020). Characterization of Ubrogepant: A Potent and Selective Antagonist of the Human Calcitonin Gene‒Related Peptide Receptor. Journal of Pharmacology and Experimental Therapeutics. 373(1). 160–166. 51 indexed citations

Ballard, Jeanine, Joshua D. Vardigan, Fuqiang Zhao, et al.. (2020). Application of Pharmacokinetic-Pharmacodynamic Modeling to Inform Translation of In Vitro NaV1.7 Inhibition to In Vivo Pharmacological Response in Non-human Primate. Pharmaceutical Research. 37(10). 181–181. 4 indexed citations

Moore, Eric L., Christopher S. Burgey, Mark E. Fraley, et al.. (2019). Characterization of Ubrogepant: A Potent and Selective Antagonist of the Human Calcitonin Gene-Related Peptide Receptor (P4.10-021). Neurology. 92(15_supplement). 2 indexed citations

Crowley, Brendan M., et al.. (2011). Expanding the scope of the Cu assisted Suzuki–Miyaura reaction. Tetrahedron Letters. 52(39). 5055–5059. 22 indexed citations

Trotter, B. Wesley, Kausik K. Nanda, Christopher S. Burgey, et al.. (2011). Imidazopyridine CB2 agonists: Optimization of CB2/CB1 selectivity and implications for in vivo analgesic efficacy. Bioorganic & Medicinal Chemistry Letters. 21(8). 2354–2358. 50 indexed citations

10.

Manley, Peter J., Daniel V. Paone, Christopher S. Burgey, et al.. (2011). Decahydroquinoline amides as highly selective CB2 agonists: Role of selectivity on in vivo efficacy in a rodent model of analgesia. Bioorganic & Medicinal Chemistry Letters. 21(8). 2359–2364. 15 indexed citations

11.

Paone, Daniel V., Diem N. Nguyen, Anthony W. Shaw, et al.. (2010). Orally bioavailable imidazoazepanes as calcitonin gene-related peptide (CGRP) receptor antagonists: Discovery of MK-2918. Bioorganic & Medicinal Chemistry Letters. 21(9). 2683–2686. 14 indexed citations

12.

Burgey, Christopher S., James Z. Deng, Scott D. Mosser, et al.. (2009). Optimization of azepanone calcitonin gene-related peptide (CGRP) receptor antagonists: Development of novel spiropiperidines. Bioorganic & Medicinal Chemistry Letters. 19(22). 6368–6372. 11 indexed citations

13.

Moore, Eric L., Christopher S. Burgey, Daniel V. Paone, et al.. (2008). Examining the binding properties of MK-0974: A CGRP receptor antagonist for the acute treatment of migraine. European Journal of Pharmacology. 602(2-3). 250–254. 21 indexed citations

14.

Paone, Daniel V., Anthony W. Shaw, Diem N. Nguyen, et al.. (2007). Potent, Orally Bioavailable Calcitonin Gene-Related Peptide Receptor Antagonists for the Treatment of Migraine: Discovery of N -[(3 R ,6 S )-6-(2,3-Difluorophenyl)-2-oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3-dihydro-1 H -imidazo[4,5- b ]pyridin- 1-yl)piperidine-1-carboxamide (MK-0974). Journal of Medicinal Chemistry. 50(23). 5564–5567. 114 indexed citations

15.

Salvatore, Christopher, James C. Hershey, John F. Fay, et al.. (2007). Pharmacological Characterization of MK-0974 [N-[(3 R,6 S)-6-(2,3-Difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1 H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a Potent and Orally Active Calcitonin Gene-Related Peptide Receptor Antagonist for the Treatment of Migraine. Journal of Pharmacology and Experimental Therapeutics. 324(2). 416–421. 115 indexed citations

16.

Shaw, Anthony W., Daniel V. Paone, Diem N. Nguyen, et al.. (2007). Caprolactams as potent CGRP receptor antagonists for the treatment of migraine. Bioorganic & Medicinal Chemistry Letters. 17(17). 4795–4798. 31 indexed citations

17.

Deng, James Z., Daniel R. McMasters, Peter Williams, et al.. (2005). Development of an oxazolopyridine series of dual thrombin/factor Xa inhibitors via structure-guided lead optimization. Bioorganic & Medicinal Chemistry Letters. 15(20). 4411–4416. 35 indexed citations

18.

Lin, Charles C., Bradley K. Wong, Christopher S. Burgey, Christopher R. Gibson, & Rominder Singh. (2005). In vitro metabolism of a thrombin inhibitor and quantitation of metabolically generated cyanide. Journal of Pharmaceutical and Biomedical Analysis. 39(5). 1014–1020. 12 indexed citations

19.

Evans, David A., Jeffrey S. Johnson, Christopher S. Burgey, & Kevin R. Campos. (1999). Reversal in enantioselectivity of tert-butyl versus phenyl-substituted bis(oxazoline) copper(II) catalyzed hetero Diels-Alder and ene reactions. Crystallographic and mechanistic studies. Tetrahedron Letters. 40(15). 2879–2882. 80 indexed citations

20.

Evans, David A., Marisa C. Kozlowski, Jerry A. Murry, et al.. (1999). C₂-Symmetric Copper(II) Complexes as Chiral Lewis Acids. Scope and Mechanism of Catalytic Enantioselective Aldol Additions of Enolsilanes to (Benzyloxy)acetaldehyde. Journal of the American Chemical Society. 121(4). 669–685. 319 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact